Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2816126 in Relapsed/Refractory Lymphomas and Solid Tumors
NCT02082977Phase 1Terminated
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of GSK126 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), non-Hodgkin lymphoma (NHL) and 3 more (10 arms), sponsored by GSK. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) up to 3.2 years, Number of Participants With Dose Limiting Toxicities (DLT) up to 4 weeks and 1 more. Started Apr 2014; status: terminated.
02
Drugs
GSK126
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)solid tumormultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02082977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082977.